Day: February 6, 2024

HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Market and that the matter is now closed. To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024. About Processa...

Criteria Change Reduces Requirements for Treatment Accessibility MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced criteria changes by Lucet Health that increase access for patients with depression to receive transcranial magnetic stimulation (TMS), such as NeuroStar® Advanced Therapy. The policy update reduces the number of antidepressant medication attempts from four down to two prior to TMS eligibility. “I am pleased to witness the collective efforts leading to improved access to mental health coverage,” stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. “We commend Lucet Health for recognizing the importance...

Issy-les-Moulineaux, February 6, 2024 Sodexo is pleased to join the 346 top-rated companies of CDP climate ranking out of 21,000 companies scored, representing two thirds of the global market capitalization. This recognition by CDP*, acknowledges the progress achieved by Sodexo on its climate ambition, both in performance and transparency. In line with its ambition to be the global leader in sustainable food and valued experiences and given the climate emergency, Sodexo is accelerating its actions to reduce its climate impact. This scoring recognises Sodexo’s ambitious trajectory and the active implication of its employees to achieve its SBTi approved Net Zero target by 2040. The integration of the most recent standards and tools to rigorously track performance and communicate transparently on climate is helping Sodexo to drive positive...

Allegiant Stadium will be outfitted with Blink Chargers accessible to employees, visitors, and the general public. Miami Beach, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) — Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global manufacturer, owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced it has been named as the official EV charging provider for Allegiant Stadium, home of the Las Vegas Raiders, providing much-needed reliable EV charging solutions for drivers. As demand and popularity for electric vehicles surge, the installation of Blink’s chargers across Allegiant Stadium stands poised to empower both fans and employees, offering them the convenience of charging their EVs. These chargers, operational 24/7, will provide EV owners with the flexibility to...

CAMARILLO, CA, Feb. 06, 2024 (GLOBE NEWSWIRE) — Sacks Parente Golf, Inc. (Nasdaq: SPGC) (“SPG” or the “Company”), a technology-forward golf company with a growing portfolio of golf products including putters, golf shafts, golf grips, and other golf-related accessories, announces the mid-February availability of golf shafts from its Newton Shafts division — starting with the Newton Motion driver shaft — in all 126 Club Champion stores nationwide. “We are thrilled to announce that our first Newton Shafts offering, the Newton Motion premium shafts, will soon be available at all Club Champion stores nationwide,” said Greg Campbell, Executive Chairman, Sacks Parente Golf. “The Newton Shaft provides unprecedented performance for all levels of golfers from the pro to the weekend warrior. We are confident that Club Champion...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree abrdn European Logistics Income plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Broker to abrdn European Logistics Income plc(d)        Date dealing undertaken: 2nd February 2024(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a...

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) — AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC). In the publication, FOTIVDA demonstrated a consistent safety profile and a long-term survival benefit in patients who were alive and progression-free at 12 months, suggesting a durable clinical benefit and safety across age groups regardless of prior treatment. “The post-hoc analysis from TIVO-3 provides additional evidence supporting the clinical utility of tivozanib in the third- or fourth-line refractory setting in patients with advanced renal cell carcinoma,” said...

The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024 NOVATO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF) in patients with Sanfilippo syndrome type A (MPS IIIA), and that sustained reduction in CSF HS exposure over time was correlated with improved long-term cognitive development. These data are from the modified intention to treat group (mITT) in the pivotal Transpher A study (N=17). The results of this study along with the additional data from the long-term follow-up study for these subjects will be presented at the WORLDSymposium™...